The Unit-VII facility is situated at Polepally Village, Jedcherla Mandal, in Mahaboobnagar district of Telangana, and is engaged in the manufacture of oral solid dosage formulations. The inspection formed part of the US FDA’s routine oversight of overseas manufacturing sites supplying products to the US market.
Aurobindo Pharma emphasized that there has been no impact on its financial position, manufacturing operations, or other business activities as a result of the inspection and the observations issued. The company reiterated that its operations at the Jedcherla unit continue as normal.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.